Sublingual Immunotherapy
Publication Date: May 1, 2017
Key Points
Key Points
- It is crucial that the practicing allergist separate the data on FDA reviewed products that have led to approval of these products (ie, dust mites, grass and ragweed tablets) from the data in the literature with other allergens and other formulations (eg, liquid formulations) that have not undergone the rigor of FDA review.
Diagnosis
...agnosis...
...le 1. World Allergy Organization Gradi...
Table 2. Description of Local Adverse Ef...
Treatment
...reatme...
...roved SLIT products for the treatment of allergic...
...e physician should be aware that SLIT may not be...
...oved SLIT products very cautiously in the pr...
...dosing equivalence between SLIT ta...
...atient’s first dose of SLIT in a...
...hrine (either an autoinjector or ot...
...nt’s SLIT dose if they have miss...
...le patients receiving SLIT therapy...
...roducts for SLIT in the United States are...
...uggested Guidelines for the Practicing Allergist...
...able 4. FDA-Approved Sublingual TabletsHaving tro...